Epsilogen Announces Completion of Oversubscribed £30.75 Million Series B Financing
HQ: UK
Founded: 2016
Series B
Sector: BioPharma
Investment Raised: GBP 30.75M €
Valuation Remains Undisclosed
Investors: 3B Future Health Fund (https://3bfuturehealth.com) ALSA Ventures (https://www.alsaventures.com) British Patient Capital (https://www.britishpatientcapital.co.uk) Caribou Property (https://www.cariboupm.com) Epidarex Capital (https://epidarex.com) Novartis Venture Fund (https://www.nvfund.com) Schroders Capital (https://www.schroders.com)